Delving into the Latest Updates on Shanghai Changsen Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Skin and Musculoskeletal Diseases

Immune System Diseases

Infectious Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Infectious Diseases	2
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	4

Top 5 Target	Count

JAK1(Tyrosine-protein kinase JAK1)	1
MDM2(p53-binding protein Mdm-2)	1
PDL1(Programmed death-ligand 1)	1
HBV capsid	1

Primary objective: To evaluate the preliminary efficacy of LW402 tablets in patients with moderate to severe AD. Secondary objective: To evaluate the safety and tolerability characteristics of LW402 tablets in patients with moderate to severe AD. Exploratory objective: To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of LW402 tablets in patients with moderate to severe AD.

Start Date11 May 2023

Sponsor / Collaborator

Shanghai Changsen Pharmaceutical Co., Ltd.

NCT06800157

/ CompletedPhase 2

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study Evaluating the Initial Efficacy, Safety, and Tolerability of LW402 Tablets in Patients with Moderate and Severe Active Rheumatoid Arthritis

The purpose of this study is to evaluate the dose-response relationship of LW402 tablets in adults with active rheumatoid arthritis combined with methotrexate, in a 12-week therapy

Start Date27 Feb 2023

Sponsor / Collaborator

Shanghai Changsen Pharmaceutical Co., Ltd.

CTR20222944

/ CompletedPhase 2

评价LW402片在中、重度活动性类风湿关节炎患者中的多中心、随机、双盲、安慰剂对照的初步疗效、安全性和耐受性的IIa期临床研究

[Translation] A multicenter, randomized, double-blind, placebo-controlled phase IIa clinical study to evaluate the preliminary efficacy, safety and tolerability of LW402 tablets in patients with moderately to severely active rheumatoid arthritis

主要目的评价LW402片在中、重度活动性类风湿关节炎（RA）患者中的初步疗效。次要目的评价LW402片在中、重度活动性RA患者中的安全性和耐受性特征。

[Translation]

Primary objective To evaluate the preliminary efficacy of LW402 tablets in patients with moderately to severely active rheumatoid arthritis (RA). Secondary objective To evaluate the safety and tolerability of LW402 tablets in patients with moderately to severely active RA.

Start Date20 Feb 2023

Sponsor / Collaborator

Shanghai Changsen Pharmaceutical Co., Ltd.

100 Clinical Results associated with Shanghai Changsen Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Changsen Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Changsen Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Changsen Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 03 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

1

Phase 1

Phase 2

2

5

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

LW-231 ( HBV capsid )	Hepatitis B, Chronic More	Phase 2
LW-402 ( JAK1 )	Ankylosing Spondylitis More	Phase 1
LW-347 ( PDL1 )	Neoplasms More	Phase 1
LW-108 ( MDM2 )	Neoplasms More	IND Application
LW-101	Neoplasms More	Discontinued